SCHEMBL814827

SCHEMBL814827

CCOC(=O)C(C)(C)Oc1ccc(C(C)=O)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 6/20 0.69
ABCB11 O95342 2/20 0.69
CYP1A2 P05177 2/20 0.69
CYP3A4 P08684 2/20 0.69
TSHR P16473 2/20 0.69
HTR2A P28223 2/20 0.69
PMP22 Q01453 2/20 0.69
FBP1 P09467 7/20 0.56
PPARG P37231 5/20 0.52
OPRK1 P41145 1/20 0.48
MAPT P10636 2/20 0.47
HPGD P15428 2/20 0.47
RAB9A P51151 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.46
GAA P10253 1/20 0.45
ALDH1A1 P00352 1/20 0.44
MEN1 O00255 1/20 0.43
USP2 O75604 1/20 0.43
LMNA P02545 1/20 0.43
ADORA3 P0DMS8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14254637 0.87 PPARA (0.69) PPARAABCB11CYP1A2CYP3A4TSHR
SCHEMBL23582375 0.86 PPARA (0.68) PPARAABCB11CYP1A2CYP3A4TSHR
SCHEMBL11548436 0.85 PPARA (0.76) PPARAABCB11CYP1A2CYP3A4TSHR
SCHEMBL3903999 0.85 PPARA (0.76) PPARAABCB11CYP1A2CYP3A4TSHR
SCHEMBL3483995 0.84 PPARA (0.66) PPARAABCB11CYP1A2CYP3A4TSHR
SCHEMBL199420 0.83 PPARA (0.73) PPARAABCB11CYP1A2CYP3A4TSHR
SCHEMBL7979408 0.83 PPARA (0.73) PPARAABCB11CYP1A2CYP3A4TSHR
SCHEMBL31118040 0.83 PPARA (0.64) PPARAABCB11CYP1A2CYP3A4TSHR
SCHEMBL8924845 0.83 PPARA (0.64) PPARAABCB11CYP1A2CYP3A4TSHR
SCHEMBL13763797 0.82 PPARA (0.71) PPARAABCB11CYP1A2CYP3A4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680343-A1 PROTEIN-PROTEIN INTERACTION STABILIZERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-01-21 EP disclosed
EP-4021901-B1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2025-09-24 EP disclosed
US-20240400563-A1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL-MYERS SQUIBB COMPANY 2024-12-05 US disclosed
WO-2024192415-A1 PROTEIN-PROTEIN INTERACTION STABILIZERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-09-19 WO disclosed
CN-114302884-B Substituted pyridopyrimidinone compounds useful as T cell activators 百时美施贵宝公司 2024-06-04 CN disclosed
US-20230151007-A1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2023-05-18 US disclosed
US-20230151007-A1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2023-05-18 US disclosed
US-11584747-B2 Substituted pyridopyrimidinonyl compounds useful as T cell activators SYNGENE INTERNATIONAL LIMITED (IN) 2023-02-21 US disclosed
US-11584747-B2 Substituted pyridopyrimidinonyl compounds useful as T cell activators SYNGENE INTERNATIONAL LIMITED (IN) 2023-02-21 US disclosed
EP-4021901-A1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS Bristol-Myers Squibb Company (US) 2022-07-06 EP disclosed
EP-1525177-B1 SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF GENFIT (FR) 2007-06-27 EP disclosed
EP-1519908-B1 COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF GENFIT (FR) 2007-06-13 EP disclosed
US-20070032543-A1 Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients GENFIT (FR) 2007-02-08 US disclosed
US-20070032543-A1 Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients GENFIT (FR) 2007-02-08 US disclosed
US-6316493-B1 FOR THERAPY OF MALARIA COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2001-11-13 US disclosed
US-5627205-A ANTILIPEMIC AGENTS AND ANTIOXIDANTS ADIR ET COMPAGNIE (FR) 1997-05-06 US disclosed
US-5512595-A FOR SUPPRESSION OF MEMBRANE LIPID PEROXIDATION, ANTILIPEMIC AGENTS ADIR ET COMPAGNIE (FR) 1996-04-30 US disclosed
EP-0142979-B1 IMPROVEMENTS IN THE PRODUCTION OF HALOCYCLOPROPYL-SUBSTITUTED PHENOXYALKANOIC ACIDS AND ESTERS STERWIN AG. (CH) 1989-02-01 EP disclosed
EP-0142979-A2 Improvements in the production of halocyclopropyl-substituted phenoxyalkanoic acids and esters STERWIN AG. (CH) 1985-05-29 EP disclosed
US-4105790-A ANTICOAGULANTS IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) 1978-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584747-B2 Substituted pyridopyrimidinonyl compounds useful as T cell activators DGKZ, DGKA, DGKG PPARA 1145/4885ABCB11 4110/4885CYP1A2 4522/4885
US-20240400563-A1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS DGKZ, DGKA, DGKG PPARA 1145/4885ABCB11 4110/4885CYP1A2 4522/4885
US-20070032543-A1 Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients PSEN1, BACE1, PSEN2 PPARA 69/4885ABCB11 4084/4885CYP1A2 1583/4885
US-20230151007-A1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS DGKZ, DGKA, DGKG PPARA 929/4885ABCB11 4118/4885CYP1A2 4202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.